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AbstrAct
Immunotherapy of cancer envisions the adoptive transfer of T-cells genetically 
engineered with tumor-specific heterodimeric α/β T-cell receptors (TCRα/β). 
However, potential mispairing of introduced TCRα/β-chains with endogenous β/α-
ones may evoke unpredictable autoimmune reactivities. A novel single chain (sc)
TCR format relies on the fusion of the Vα-Linker-Vβ-fragment to the TCR Cβ-domain 
and coexpression of the TCR Cα-domain capable of recruiting the natural CD3-
complex for full and hence, native T-cell signaling. Here, we tested whether such 
a gp100(280-288)- or p53(264-272) tumor antigen-specific scTCR is still prone to 
mispairing with TCRα. In a human Jurkat-76 T-cell line lacking endogenous TCRs, 
surface expression and function of a scTCR could be reconstituted by any cointroduced 
TCRα-chain indicating mispairing to take place on a molecular basis. In contrast, 
transduction into human TCRα/β-positive T-cells revealed that mispairing is largely 
reduced. Competition experiments in Jurkat-76 confirmed the preference of dcTCR to 
selfpair and to spare scTCR. This also allowed for the generation of dc/scTCR-modified 
cytomegalovirus/tumor antigen-bispecific T-cells to augment T-cell activation in 
CMV-infected tumor patients. Residual mispairing was prevented by strenghtening 
Oncotarget21200www.impactjournals.com/oncotarget
IntroductIon
T-cell receptors (TCR) are immunglobulin-like 
folded membrane proteins expressed on CD4+ / CD8+ 
T-cells with the ability to recognize complexes of 
processed peptides associated with MHC-molecules 
on antigen presenting cells (APC). Current strategies 
in immunotherapy of cancer aim at equipping patients’ 
T-cells with tumor reactive TCRs by e.g. retroviral gene 
transfer ex vivo and to reinfuse them systemically. In 
several clinical trials a large benefit for the patient in 
reducing or even extinguishing tumor burden has been 
demonstrated [1]. 
However, the heterologous overexpression of the 
TCR in T-cells necessitates optimization of the TCR 
framework to accomplish biochemical inertness against 
endogenous TCRs. Indeed, since firstly, the TCR is a 
heterodimer comprising TCRα- and TCRβ-chain and 
secondly, the retroviral introduction of an exogenous TCR 
does not override expression of the endogenous TCR, the 
formation of mixed TCR chain pairing with unpredictable 
consequences on self-antigen recognition is a distinct 
possibility [2]. At worst, neoreactivities which end up with 
autoimmunity [3, 4] may impose severe adverse reactions 
in adoptive TCR gene transfer-based clinical trials. Thus, 
major efforts have been invested into the design of TCRs 
endowed with preferential expression over endogenous 
TCRs [5-7], the mutual exclusion to interact with 
endogenous TCRs [8], or high-affinity antigen recognition 
[9]. Alternatively, endogenous TCRs have been targeted in 
T-cells via sequence-specific siRNA-technology [10], or 
genomic editing by zinc finger nucleases [11], or TALENs 
[12].
One common approach relies on the generation 
of single chain TCR (scTCR)-fragments by covalently 
bridging the antigen-recognizing V-domains with a 15-
20mer of a Glycine/Serine-rich linker (Li) which in 
theory, inhibits mispairing due to sterical hindrance [13]. 
Transport to the cell membrane and provision of T-cell 
signaling upon antigen encounter is accomplished by 
fusion to the CD3ζ-chain as pioneered by Z. Eshhar for 
chimeric antigen receptor (CAR)-engineered T-cells [14]. 
The chimeric immunoreceptor construct assembles to 
homodimers and operates outside the TCR/CD3-complex 
which is believed to make mispairing with endogenous 
TCRs highly unlikely [15, 16]. A recent innovation by 
this design is the fusion to the TCR Cβ-domain yielding a 
Vα-Li-Vβ-Cβ 3-domain scTCR which then is coexpressed 
with a truncated TCRα-chain merely comprising the Cα-
domain [17]. Cytotoxicity of scTCR gp100 tranduced 
T-cells against human melanoma was as efficient as those 
transduced with the wild type dcTCR in vitro. Moreover, 
they caused a significant delay of tumor growth in 
NOD/SCID-mice. Notably, this 4-domain topology 
highly resembles the native TCR architecture so as to 
accomplish the entire assembly of the TCR/CD3-complex, 
subsequently leading to a more physiologic proximal T-cell 
signaling cascade [18]. Cα is crucial for the recruitment 
of CD3ζ and CD3δε to the TCR/CD3-complex [19]. 
Chimerization to mouse Cα/Cβ-domains or murinization 
of a few residues was proven to be necessary to provide 
for a tight interaction between Cα and Cβ [5, 20, 21]. 
However, integration into the native CD3-complex may 
not only restrict expression due to limiting components 
of the multimeric CD3-complex [22] but may also evoke 
mispairing [16]. The interaction of TCRα and TCRβ is 
largely governed by the extensive Cα/Cβ-interface [23], 
by the individual TCR subfamily V-domains, and also by 
the antigen-specific CDR3α/β-loops juxtaposed on top of 
the Vα/Vβ-interface [24]. TCRαβ heterodimer formation 
is a prerequisite for fully competent TCR/CD3-complex 
assembly and T-cell signaling. TCRs that prefer to interact 
with themselves are referred to as ‘strong’ or ‘dominant’ 
TCRs [25] being able to outcompete ‘weak’ TCRs for 
binding to the limiting CD3 complex [22]. 
Here, we prompted us to verify whether such 
a novel scTCR still tends to mispair with TCRα in a 
noncompetitive environment of the human leukemia 
T-cell line Jurkat-76 (J-76) lacking the expression of an 
endogenous TCR [26], or in the competitive environment 
of bulk human T-cells. We established a model to 
unequivocally assign mispairing to the interaction with 
a full length TCRα-chain, the latter contributing with its 
CDR3α-loop to antigen recognition: For this, we generated 
a mutated scTCR CDR3α incapable of binding the cognate 
antigen and coexpressed it with wild type TCRα of the 
same antigen specificity serving as a ‘surrogate’ for 
the Vα-Li-Vβ-fragment through the design of a novel disulfide bond between a Vα- 
and a linker-resident residue close to Vβ. Multimer-stainings, and cytotoxicity-, 
IFNγ-secretion-, and CFSE-proliferation-assays, the latter towards dendritic cells 
endogenously processing RNA-electroporated gp100 antigen proved the absence 
of hybrid scTCR/TCRα-formation without impairing avidity of scTCR/Cα in T-cells. 
Moreover, a fragile cytomegalovirus pp65(495-503)-specific scTCR modified this 
way acquired enhanced cytotoxicity. Thus, optimized scTCR/Cα inhibits residual TCR 
mispairing to accomplish safe adoptive immunotherapy for bulk endogenous TCRα/β-
positive T-cells.
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any endogenous one, to assess reconstitution of antigen 
recognition. This issue has experimentally been assessed 
for 2 independent expression systems based on a retroviral 
[8, 27] or RNA vector [28, 29] for 2 different high-affinity 
TCRs, a human A2-restricted TCR of the gp100(280-
288)-antigen specificity isolated from TILs [30], and a 
murine A2-restricted TCR of the p53(264-272)-antigen 
specificity isolated from A2-transgenic mice after peptide 
immunization [31]. We also mimicked a competitive 
situation in J-76 by introducing different TCR chain 
combinations via RNA electroporation. Moreover, we 
quantified the relative expression levels of a ‘strong’ 
gp100- or p53-specific scTCR and a ‘weak’ CMV-specific 
dcTCR in antigen-bispecific J-76 and T-cells, respectively, 
for e.g. the treatment of immunosuppressed CMV+ 
leukemia patients after bone marrow transplantation [32]. 
TCR-engineered T-cells were tested for their structural 
avidities in multimer-binding by flow cytometry, and 
for functional avidities by IFNγ-secretion, cytotoxicity, 
or proliferation. We also assessed the magnitude of 
mispairing for saturating amounts of pulsed peptide versus 
endogenous processing of full length antigen following 
RNA electroporation in autologous iDCs as target cells. 
Finally, we aimed at strengthening V-domain pairing 
by the design of a novel disulfide bond into a scTCR-
fragment [33] so as to eradicate traceable mispairing with 
any TCRα. 
results
A human 3-domain sctcr gp100(280-288) 
mispairs with human TCRα in human Jurkat-76 
cells devoid of endogenous tcrs
The endogenous TCRα/β-chain deficient Jurkat-76 
(J-76) leukemia T-cell line [26] was used to perform TCR 
mispairing studies. Absence of surface expression of TCRs 
was confirmed, also for the TCR-associated CD3-complex 
(Suppl. Figure 1A). Moreover, RNA electroporation [34] 
of a single TCRα- or TCRβ-chain did not reconstitute pan 
TCR-expression which might have taken place by pairing 
with an endogenous TCRβ- or TCRα-chain proving that 
the genomic defect affected both chains. In contrast, 
introduction of both TCR-chains, a wild type TCRαβ 
Figure 1: Mispairing of a human scTCR gp100 with a full length human TCRα gp100-chain takes place in Jurkat-76. 
A./B. 5 x 106 J-76 cells were electroporated with 5µg RNA coding for different scTCR gp100 constructs and mouse Cα, the latter required 
for surface expression. After 12 hours, TCR expression was analyzed cytofluorometrically either with a subfamily-specific antibody Vβ14 
or by tetramer (Tet) gp100(280-288) -staining. Mouse Cβ-chimerized (Chim) scTCR gp100 was analyzed for a potential mispairing with Hu 
Wt TCRα gp100. TCRα operates as a ‘surrogate’ for any (endogenous) TCRα and hence, as a ‘sensor’ of mispairing. The mean fluorescence 
intensity (MFI) for every specimen is indicated. C./D. A corresponding panel of TCR gp100 constructs as in (A) were introduced into J-76 
via retroviral gene transfer and normalized for gene expression by drug-selection. Hu Chim scTCR gp100, either coexpressed with Mu Ca 
(left, (-)) or Wt TCRα gp100 (middle, (…)), was analyzed for its surface expression with an anti-mouse TCRβ-specific antibody (density 
plots) or antigen-specific multimer binding (overlay histogram), functionally unresponsive or so-called ‘silenced’ Hu Chim scTCR gp100 
silCDR3α correspondingly in D. Experiment was performed twice.
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gp100, or a TCRαβ pp65, and of notice, ‘mispaired’ TCRα 
gp100 with TCRβ pp65 (and vice versa) led to pronounced 
human (Hu) pan TCR- or TCR-subfamily-specific staining 
(Suppl. Figure 1B/1C). 
Hence, J-76 cells allow for the unbiased 
characterization of molecular interactions between 
any introduced TCR-chains without interference from 
endogenous TCRαβ counterparts. Therefore this system 
is also suited for pairing analysis between an introduced 
scTCR and TCRα-chains of any antigen specificity. 
The design and nomenclature for all un/modified TCR 
constructs used here are outlined in Suppl. Figure 1D. 
Since the scTCR framework to be scrutinized is of the 
domain order Vα-Li-Vβ-Cβ [17] mispairing with a TCRβ-
chain was, as expected, experimentally ruled out (data not 
shown). 
We used TCR RNA electroporation to introduce 
high-affinity TCR gp100 [30] coding sequences into J-76 
[28, 34] which enables fast expression within hours in a 
quantitative manner. A prerequisite for scTCR expression 
according to our design was the coexpression of the mouse 
(Mu) Cα-domain [17] which triggers the recruitment of 
the CD3 subunits obligatory for cell surface expression 
as shown for subfamily- or antigen-specific multimer-
staining (Figure 1A, MFIs 601, 158). Additionally, human 
scTCR gp100 needed to be chimerized (chim) to mouse 
Cβ so as to exploit stronger murine Cα/Cβ-pairing and 
interaction with human CD3 [5]. ScTCR gp100(280-
288) alone elicited a weak signal in TCRβ-specific Vβ14-
staining (MFI 30.7) and no specific signal in antigen-
specific multimer-staining (MFI 8.1). The expression of 
scTCRgp100 + TCRα gp100 led to a profound Vβ14-
surface expression (MFI 318) and most importantly, 
antigen recognition (MFI Tet 48.7) which wasn’t expected 
to take place to such an extent. Hence, the fused 3-domain 
scTCR gp100 was able to interact with TCRα gp100 
of the same antigen-specificity and suggested, that the 
single chain configuration did not prevent mispairing on 
a molecular basis.
Next, we mutated the CDR3-region of the scTCR 
Vα-domain to S109Q according to IMGT nomenclature 
[35] to eliminate or ‘silence’ (sil) antigen recognition 
(silCDR3α) without affecting expression (Figure 1B), 
thereby generating a functionally unresponsive scTCR. 
Hypothetically, this allowed to unambiguously answer 
the question whether a (silenced) scTCR is able to pair 
with the full length TCRα-chain (i.e. Vα + Cα, herein 
referred to as ‘TCRα-mispairing’) of the same antigen-
specificity to restore antigen recognition in trans (i.e. from 
2 polypeptides). In general, TCRα-chains of the same 
antigen specificity turned out to be a ‘sensor’ of mispairing 
by means of multimer stainings or effector function and 
therefore, will be referred to as a ‘surrogate’ for any (i.e. 
human endogenous) TCRα-chain. More indirectly, TCRβ-
positivity of a (non-silenced) scTCR in the absence of 
multimer-binding suggests also an identical mechanism 
of TCRα-mispairing since both domains of the latter, Vα 
and Cα, seemingly mispair (e.g. Figure 4C). Alternatively, 
a (non-silenced) scTCR may just need to pair with the Cα-
domain of an unrelated TCRα (referred to as ‘TCR Cα-
mispairing’) to preserve antigen-recognition in cis (i.e. 
from the scTCR polypeptide alone). We supposed, that 
partial unfolding and/or domain dissociation of a scTCR-
fragment (i.e. Vα-Li-Vβ) as observed for scFv-fragments 
(VH-Li-VL) [36], may allow this side reaction. 
Mutation of CDR3α did not impair expression of 
the scTCR (MFI 553) while antigen recognition was 
abolished (MFI 8.1). Moreover, expression of scTCR 
gp100 silCDR3α + Cα was even higher than for a wild 
type human double chain TCR (MFI 221) which could 
be attributed to the murinized C-domains of scTCR 
gp100 [17]. Again, coexpression of a full length TCRα 
gp100 led to a marked Vβ14-expression (MFI 291). Most 
importantly, multimer binding could still be restored in 
part (MFI 28.9) by TCRα which clearly proved that scTCR 
gp100 silCDR3α has the potential not only to molecularly 
associate with the full length TCRα gp100-chain, but also 
to restore antigen recognition in trans despite the presence 
of a bulky linker-attached Vα-domain. The higher level of 
antigen recognition of non-silenced scTCR gp100 + TCRα 
in comparison to scTCR silCDR3α + TCRα (MFI, 48.7 
vs 28.9) may likely arise from mispairing caused by both, 
TCRα- and also but less by TCR Cα-mispairing. 
Pairing of scTCR gp100 with the homologous 
TCRα -chain was also studied in a clinically more relevant 
retroviral expression system in J-76 (Figure 1C/1D). 
Transduced Jurkat-76 were drug-selected and expanded 
to normalize TCR expression [8]. Mu TCRβ-expression 
of scTCR gp100 + Cα (MFIx 481.9) and scTCR gp100 
silCDR3α + Cα (MFI 410.6) was in the same range 
(Figure 1C vs 1D) while for the latter tetramer binding 
dropped down to background (MFIs 19.9 vs 239.1). 
Moreover, increase in TCR expression correlated with 
elevated amounts of CD3 surface expression while scTCR 
gp100 alone failed (data not shown). Again, coexpression 
of TCRα gp100 proved to partially restore tetramer 
binding (scTCR + TCRα, MFI 43.5; scTCR silCDR3α + 
TCRα, MFI 39.7) and in addition, the transport of CD3 to 
the cell surface (MFIy 7.2, 6.9). 
Murinization of human double chain TCRs [5] or 
single chain TCRs [17] in their TCR C-domains supported 
TCR expression by favourable chain pairing due to 
distinct species-specific amino acid interactions at their 
C-domains’ interface [20]. According to our previous 
findings, mispairing of a chimerized scTCR should be 
more pronounced with a murinized human TCRα than 
with a full length human one. To test this, we combined 
Hu Chim scTCR gp100 with either a human or murinized 
TCRα gp100 or TCRα pp65-chain by RNA electroporation 
into J-76 followed by expression analysis and functional 
validation in a peptide-titrated IFNγ-Elispot assay (Suppl. 
Figure 2A). Vβ14-staining, and of note, tetramer-positivity 
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and IFNγ-secretion were indeed higher for the murinized 
TCRα gp100-chain. Additionally, a higher gp100 tetramer-
positivity for Chim scTCR gp100 in combination with 
unrelated Chim TCRα pp65 substantiated the proposed 
mechanism of TCR Cα-mispairing. 
A mouse 3-domain scTCR p53(264-272) mispairs 
with human and mouse TCRα in human 
Jurkat-76
Next, we assessed the amount of hybrid TCR 
formation for a murine high-affinity scTCR p53(264-
272) originating from A2-transgenic mice [31] which 
followed the same design of a scTCR gp100 + Cα (Suppl. 
Figure 1D). J-76 cells were retrovirally transduced 
with scTCR p53 along with Mu Cα or species-related 
or unrelated TCRα-chains, respectively (Suppl. Figure 
2B). Functionally unresponsive (i.e. CDR3α D109A) 
scTCRp53 elicited exclusively TCRα-mispairing (not TCR 
Cα-mispairing) in particular with species-related mouse 
but also with human TCRα-chains. Only the provision 
of Mu Cα or TCRα p53 led to a recovery in multimer-
binding, which was also prominent in an IFNγ -secretion 
assay (Suppl. Figure 2C). The order of mispairing is in 
line with experiments conducted with the functionally 
competent scTCR p53 (corresponding data only shown for 
T-cells in Figure 4C). Taken together, by taking advantage 
of a silencing mutation in TCR CDR3α our results clearly 
demonstrated the incidence of TCRα-mispairing with a 
3-domain single chain TCR for a (chimerized) human and 
a mouse scTCR on a molecular basis in the absence of 
potentially interfering endogenous TCRα/β-chains. 
Competition of TCR α-chains (i.e. Cα versus 
TCRα) for binding to a scTCR: Cα is able to 
compete with any TCRα depending on their 
intrinsic competitive strengths
In human T-cells, introduced Cα will have to 
compete with endogenous TCRα for binding to a scTCR. 
To mimic the competitive situation scTCR gp100 was 
coelectroporated with Cα and Hu Wt TCRα pp65 in J-76 
cells (Figure 2A). The presence of TCRα did not affect 
the expression of scTCR gp100 significantly (Vβ14, MFI 
123) when compared to the expression in the absence 
of the competitive chain (MFI 206). Therefore, TCRα 
pp65 seemingly competed only weakly for binding to 
Chim scTCR gp100. However, it is difficult to discern, 
whether the observed Vβ14-positivity is due to pairing 
of the scTCR to Cα or TCRα. Hence, only recovery 
of antigen binding would give an unbiased answer 
towards the preferred interaction: Notably, the presence 
of TCRα did only moderately affect tetramer binding 
(Tet, MFI 43.2) in comparison to the absence of TCRα 
(MFI 98.9). Thus, although TCRα is able to pair with 
the scTCR via 2 domains, namely Cα/Cβ and Vα/Vβ 
at the expense of displacing Vα of the scTCR, pairing 
with Cα is the more likely reaction presumably because 
i) both C-domains were murinized characteristic of an 
exceptionally favorable interdomain affinity [5] and ii) 
this thermodynamically obviates the need to displace Vα 
of the scTCR. 
We assessed this relationship in more detail for a 
mouse single chain TCR p53 in a retroviral vector system 
for which various human TCRα-chains of different antigen 
specificities were available (Figure 2B). The scTCR p53 
was encoded together with Mu Cα on a single retroviral 
vector via a self-processing element F2A [37]. This 
plasmid was transduced alone or in combination with 
either a human pp65(495-503)-, gp100(280-288)-, AML 
[38]-, or murine p53(264-272)-, MDM2(81-88) TCRα-
encoding plasmid and normalized in protein expression 
by combined drug-selection. Coexpression of TCRα pp65 
did not affect multimer staining (MFI 28.4) in relation 
to scTCR p53-F2A-Cα alone (MFI 24.8). As shown 
before, TCRα pp65 was poorly able to outcompete Cα. 
TCRα p53(264-272) which behaved as a normalization 
control here, reduced expression only slightly (19.6) as 
to be expected. TCRα gp100-chain exhibited a lower 
tetramer positivity (MFI 15.9) denoting a somewhat more 
pronounced competition than TCRα pp65. Coexpression of 
a human AML-reactive TCRα further decreased tetramer 
binding a little (MFI 14.1). Mouse TCRα MDM2 turned 
out to be the most potent competitor (MFI 7.5) presumably 
due to the higher interaction forces between mouse Cα/
Cβ as discussed before and hypothetically, also between 
mouse Vα/Vβ. Importantly, none of the scrutinized TCRα-
chains were able to entirely suppress pairing with Cα. 
This may have important implications for gene therapy in 
future scTCR + Cα - based clinical trials. The rank order 
of mispairing behaviour in the presence of Cα and any 
TCRα could be recovered in an peptide-titrated IFNγ-
ELISA (data not shown): Even in the presence of the best 
suppressor of scTCR p53/Cα - expression, mouse TCRα 
MDM2, substantial amounts of IFNγ upon p53(264-272) 
antigen encounter were secreted. 
Competition of TCR β-chains (i.e. TCRβ versus 
scTCR) for binding to TCRα: TCRβ dominates 
binding to TCRα to assemble to a native TCRαβ
We stated in the previous section that a CMV-
specific TCRα pp65-chain is weakly competing for 
binding to both, a scTCR gp100 and scTCR p53 (Figure 
2A/2B) in the presence of Cα. Next, we asked whether 
such a ‘weak’ TCRα-chain is biased to predominantly 
interact with its designated binding partner, TCRβ pp65, 
or in other words, whether TCRβ preferentially binds 
to TCRα rather than a scTCR. In RNA electroporation 
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experiments with J-76, TCRα pp65 is able to interact 
with a scTCR gp100 in the absence of Cα (Figure 2C, 
MFI 61.5). Since TCRα- and not TCR Cα-mispairing 
apparently took place this combination did not elicit any 
tetramer-positivity (MFI 6.1). When supplying TCRβ 
pp65 Vβ14 expression of scTCR gp100 dropped down 
to background as of scTCR alone (MFI 12.5), the same 
was true for tetramer staining (MFI 6.0). Obviously, 
TCRβ pp65 is able to entirely capture TCRα pp65 and to 
withdraw it from scTCR gp100. Most importantly, TCRβ 
pp65-specific Vβ13-staining and in particular, CMV(495-
503) tetramer-positivity of TCRαβ pp65 in the presence of 
scTCR gp100 gave rise to a level (MFI 102) comparable to 
TCRαβ pp65 in the absence of scTCR gp100 (MFI 104). 
This highlights, that TCRβ pp65 entirely outcompeted 
scTCR for binding to its designated counterpart, TCRα 
pp65-chain, an observation that could also be confirmed 
in an IFNγ-Elispot-assay (data not shown). 
However, this might merely reflect a bias towards 
chain pairing of thymically coevolved dcTCR chains 
Figure 2: Competitive TCR-chain pairing analyses in Jurkat-76. (A./B.) Competition of TCRα and Cα for binding to scTCR 
gp100. A. 5 x 106 J-76 cells were RNA-electroporated with 5µg RNA coding for Cα, scTCR gp100 and TCRα pp65. TCR expression was 
analyzed by flow cytometry as outlined in Figure 1. B. Jurkat cells were retrovirally transduced with scTCR p53-F2A-Cα and TCRα of 
different antigen-specificities and species-origins, drug-selected, expanded, and analyzed by flow cytometry. (c./d.) Competition of TCRβ 
and scTCR for binding to TCRα. The RNA-electroporation experiment was performed as described in (A). C. Chimerized scTCR gp100 
was coexpressed with TCRαβ of the pp65(495-503)-specificity and tested for Vβ14 (TCR gp100)- or Vβ13.1 (TCR pp65)-, and tetramer 
gp100- or pp65-positivity. D. Functionally unresponsive scTCR gp100 silCDR3α was coexpressed with unmodified TCRα gp100 and 
different antigen-unrelated CMV (pp65 or IE1)-specific TCRβ-chains. Experiment was performed twice.
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on a clonal level. To address this argument, we took 
advantage of the S109Q-silenced scTCR gp100 to 
verify whether Hu TCRα gp100 would either restore 
gp100 antigen recognition or would also be captured 
by any unrelated coexpressed TCRβ thereby abolishing 
gp100 antigen binding. We used TCRβ pp65(495-503) 
or TCRβ IE-1(316-324) specific for late or early CMV-
antigens, respectively (Figure 2D). The coelectroporation 
of scTCR gp100 silCDR3α and TCRα gp100 into J-76 
proved high Vβ14 (MFI 292)- and tetramer-staining 
(MFI 29.4) as shown before (Figure 1). Cotransfection of 
scTCR gp100 silCDR3α/TCRα gp100 with TCRβ pp65 
or TCRβ IE1-chain lowered Vβ14-staining (MFI 63.9, 
62.4) and eliminated any tetramer-positivity (MFI 7.8, 
7.3). Therefore, TCRβ-chains in general seem to dominate 
binding to TCRα gp100 over binding of the latter to 
scTCR gp100. This implicates that mispairing of a scTCR 
with TCRα in the presence of any competing TCRβ is 
rather unlikely to occur.
Dual specificities of Jurkat-76 coexpressing a 
single chain TCR gp100 and a double chain TCR 
pp65
Donor lymphocyte infusion (DLI) takes into 
consideration the adoptive transfer of dual-specific T-cells 
carrying a tumor-associated antigen (TAA)-specific 
engineered TCR along with a CMV-specific endogenous 
TCR to simultaneously treat refractory leukemias and 
CMV-reactivation in immunosuppressed patients after 
bone marrow transplantation [32]. Also, virus/TAA-
bispecific T-cells hold great promise to operate more 
efficiently and to persist longterm in tumor patients due 
to the long-lasting stimulus by latent viruses such as EBV 
[39]. In a proof of concept, we initially tested in J-76 the 
option to coexpress a tumor-reactive scTCR gp100 + Cα 
and a CMV-specific dcTCR pp65, the latter one which 
mimics the endogenous TCR pp65 in a CMV-specific 
Figure 3: Dual specificities of a scTCR gp100 and a dcTCR pp65 in Jurkat-76. 5 x 106 J-76 cells were electroporated with 5µg 
RNA coding for Cα, or TCRα, TCRβ of the CMV-specificity, or Chim scTCR of the gp100-specificity. A. Single or combined expression 
of Chim scTCR gp100 + Cα and dcTCRαβ pp65 was analyzed cytofluorometrically either with a TCR subfamily-specific antibody vβ14 
(gp100, left overlay) or vβ13.1 (pp65, right overlay). B. The expression of both TCRs as described in (A) were quantified (MFIs in both 
dimensions) by pp65(495-503)- or gp100(280-288)-specific tetramer stainings. C. 20h-ELIspot assay against dose-dependently peptide 
loaded T2 for an E:T-ratio = 0.3:1 using gp100- and/or pp65-specific TCR-engineered responder cells as described in (A). Data are shown 
as mean + SD of duplicates. 
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T-cell population isolated from a CMV-positive donor. 
From previous competition experiments we knew that 
firstly, Cα (and not TCRα) predominantly associates with 
scTCR (Figure 2A/2B) and secondly, that TCRβ (and not 
scTCR) dominates association with TCRα (Figure 2C/2D). 
In theory, these features should allow for the simultaneous 
expression of a scTCR and a dcTCR in a hematopoietic 
cell. Depending on the competitive strength of TCRα and 
TCRβ, either the scTCR or the dcTCR should prevail the 
relative frequencies of their expressions. 
Electroporation of scTCR gp100 + Cα gave a 
robust Vβ14 expression in J-76 (Figure 3A, MFI 204). 
Transfection of solely scTCR along with dcTCRαβ pp65 
reduced expression as expected (MFI 9.6), while the 
addition of Cα led to a marked expression of scTCR + Cα 
in the presence of dcTCRαβ pp65 (MFI 216) comparable 
to scTCR + Cα alone. Vβ13.1-expression of dcTCRαβ 
pp65 (MFI 23.6) disappeared not before providing both, 
scTCR gp100 and Cα (MFI 7.0). ScTCR gp100 alone was 
not able to reduce expression of dcTCR pp65 (MFI 24.3). 
While when coexpressing both TCRs, scTCR gp100 + Cα 
was as prominent as the separately expressed one (MFIs 
216 vs 204), dcTCRαβ pp65 was much less expressed 
(MFIs 7 vs 23.6). This impressively shows that dcTCR 
pp65 is more susceptible for being outcompeted by scTCR 
+ Cα than vice versa and underlines the weak competitive 
strength of not only monomeric TCRα pp65 (Figure 
2A/2B) but also of the heterodimeric TCRαβ pp65. This 
could be illustrated in a 2-dimensional antigen-dependent 
flow cytometry analysis more vividly (Figure 3B): The 
tetramer-staining demonstrated strong expression of 
both, scTCR gp100 + Cα (MFI 96.7) and dcTCRαβ pp65 
(MFI 76.6) as long as they were expressed separately. 
The combined expression of both TCR formats led to a 
dominant expression of the scTCR gp100 + Cα to more 
than half of the solitary expressed scTCR (i.e. MFIs 
58.9/96.7 = 0.6) while expression of the dcTCRαβ pp65 
decreased to less than one third of the separately expressed 
one (i.e. MFIs 23.0/76.6 = 0.3). This observation could 
be reasonably well retrieved from an IFNγ-Elispot-assay 
(Figure 3C). Noteworthy, IFNγ spot formation for both 
TCR formats and specificities was roughly in the same 
range and as high as for the related TCRs expressed 
separately despite their differences in expression. 
Mispairing of a 3-domain sctcr with human 
TCRα occurs with lower frequencies in human 
t-cells
Next, we assessed the propensity of scTCR gp100 
and p53 to mispair with polyclonal endogenous TCRs 
in primary human T-cells (Figure 4). We assumed that 
the natural TCRs would interfere with pairing events on 
a broader scale than in the TCR-negative J-76 host cell. 
We RNA-electroporated [28] chimerized scTCR gp100 
into bulk human CD8+ T-cells (Figure 4A) and observed a 
modest multimer positivity (35.7 %) of low intensity (MFI 
665) presumably originating most-likely from TCR Cα-
mispairing as this also became apparent in J-76 (Figure 1A 
vs 1B). In this regard, the mock control Hu Chim scTCR 
gp100 silCDRα + Cα (3.2 %) confirmed the specificity 
of the dextramer. Coexpression of the mouse Cα-domain 
gave rise to a high frequency (77.5 %) and intensity (MFI 
1669) in multimer staining which emphasizes that Cα is 
capable of interacting with scTCR gp100 in the presence 
of a vast excess of competing polyclonal endogenous 
TCRα-chains. 
Coelectroporation of cognate TCRα gp100 
conferred moderate antigen recognition of 42.7 % 
(MFI 782) again reflecting TCR Cα-mispairing with 
endogenous and here additionally, exogenous TCRα. As 
expected, cognate antigen recognition could be eliminated 
by introducing the S109Q-mutation into Vα CDR3 (3.2 
%, MFI 126). Most importantly, the coexpression of 
TCRα gp100 in place of Cα revealed a minor but clearly 
discernible fraction of T-cells carrying a mispaired scTCR 
gp100 silCDR3α + Hu TCRα gp100 (7.3 %, MFI 155). 
Thus, a low amount of mispairing of scTCR gp100 
with TCRα gp100 became imminent in the competitive 
environment of TCR polyclonal T-cells and hence, will 
be referred to as ‘residual mispairing’. We hypothesize 
that beside TCRα gp100 as a ‘surrogate’ for any TCRα-
chain mispairing of arbitrary endogenous TCRα-chains 
of an appropriate interchain affinity is also likely to 
occur. Worth mentioning, that its low frequency is in line 
with data obtained in J-76, that murine Cα successfully 
outcompeted endogenous TCRα for binding to chimerized 
scTCR (Figure 2A/2B) and that the majority of TCRα-
chains tended to assemble with TCRβ to double chain 
TCRαβ (Figure 2C/2D). 
We also addressed mispairing of the high-affinity 
mouse TCR p53 in human primary T-cells (Figure 4B). 
Two plasmids encoding either a wild type or functionally 
unresponsive scTCR p53 silCDR3α along with Cα or any 
complementary TCRα-chain were retrovirally transduced 
and enriched for gene expression in human T-cells as 
described before. Here, TCR Cα-mispairing of arbitrary 
endogenous TCRα was not detectable (MFI 4.3) as 
judged from expression of scTCR p53 alone. A fraction of 
T-cells transduced with scTCR p53 + Cα was positive for 
tetramer staining (CD8+ MFI 29.1). ScTCR p53 silCDR3α 
transduced along with Cα or any other unrelated TCRα-
chain did not recognize the cognate antigen as expected 
(MFI 3.9, 4.2). In contrast, coexpression of the related 
TCRα p53-chain restored substantial amounts of antigen 
recognition (MFI 37.1), suggesting more mispairing to 
take place for a mouse scTCR as opposed to a human 
(even chimerized) one (Figure 4A). 
Next, we wanted to verify the variable competitive 
strengths of different TCRα-chains of varying species and 
TCR subfamily affiliation for CD4+ and CD8+ T-cells 
Oncotarget21207www.impactjournals.com/oncotarget
in analogy to J-76 data (Figure 2B) but in the presence 
of polyclonal endogenous TCRs. In flow cytometry- and 
IFNγ-secretion analyses (Suppl. Figure 3A) we indeed 
observed the same trend: A mouse TCRα MDM2 was 
the most potent chain (MFIs CD4+ 10.5, CD8+ 23.6), for 
reasons as outlined before. In conclusion, the relative 
mispairing potential (i.e. the competitive strength) of a 
particular TCRα-chain to associate with a scTCR remains 
unaltered in the presence of polyclonal endogenous TCRs. 
We observed some TCR Cα-mispairing for Hu Chim 
scTCR gp100 (Figure 4A) but not for Mu scTCR p53 
(Figure 4B) in human T-cells, which we speculated to stem 
from a higher structural rigidity, i.e. stable folding, of a 
mouse scTCR-fragment (i.e. Vα-Li-Vβ). Hence, we tested 
this hypothesis by querying whether a higher competitive 
strength of any unrelated TCRα-chain, in particular a 
murine one, might evoke TCR Cα-mispairing (Figure 4C) 
as previously shown to be the case for a murinized TCRα-
chain in J-76 (Suppl. Figure 2A). Expression analyses 
with human and mouse TCRα-chains demonstrated that 
mouse specimens achieved much higher scTCR p53 Vβ3-
expression rates (even higher than Mu Cα (MFI 116)) 
than human ones (MFIs 146 and 137 vs 16, 13.8). The 
latter were in the range of the negative control scTCR 
p53 alone (MFI 21.7) leaving us to conclude that the 
human TCRα inspected here tentatively pair with a mouse 
scTCR. They didn’t undergo neither TCRα- nor TCR Cα-
mispairing. However, scTCR p53 alone exhibited a faint 
signal above the mock signal (MFI 4.0) that likely resulted 
from some interaction with any endogenous human TCRα 
in bulk T-cells. Consistently, only coexpression of the 
antigen-related TCRα p53-chain led to multimer-binding 
(MFI 16.1) while none of the TCRα-chains of varying 
competitive strengths, even TCRα MDM2 (Figure 2B, 
Suppl. Figure 3A), owing to their species origin or TCR 
subfamily affiliation were able to reconstitute tetramer 
binding (MFIs 2.6): Although the ‘strong’ species-
related Mu TCRα MDM2 led to marked Vβ3-expression 
of scTCR p53 in accordance with Suppl. Figure 2B for 
Jurkat-76, no tetramer-staining was observed. Thus, 
the stable folding of a mouse scTCR allows TCRα-
mispairing only with species-related but hardly ever with 
human (‘weak’) ones. The results of Figures 4A-4C were 
confirmed in IFNγ-secretion assays (scTCR p53: Suppl. 
Figure 3B/3C, scTCR gp100: Suppl. Figure 4).
From this we conclude that TCRα-mispairing is 
favored over TCR Cα-mispairing due to the larger sum 
of interaction forces between mouse V- and C-domains 
(see also explanations in paragraph to Figure 1A/1B). In 
general, TCR Cα-mispairing may become only prominent 
for strong interactions between C-domains and weaker 
(also transient) interactions between V-domains. TCR 
chains characterized by weak interactions between V- 
and C-domains just dissociate. Eventually, to reconcile 
the different behavior of human versus mouse scTCRs 
in human T-cells we propose a mechanism by which the 
Vα-domain of any endogenous human TCRα ‘senses’ the 
presence of a human or mouse Vβ-domain in a 3-domain 
single chain TCR to contribute to inter-chain binding 
which eventually determines the relative amount of TCRα- 
versus TCR Cα-mispairing, and dissociation, respectively 
(Suppl. Figure 5).
Dual specificities of endogenously pp65-specific 
T-cells equipped with scTCR p53
Previous results showed that in human T-cells a 
human TCRα poorly associates with a mouse scTCR 
p53 (Figure 4C) and that it was hardly able to compete 
with Cα for binding to scTCR p53 (Suppl. Figure 3A). 
This in turn supports the idea that endogenous TCRβ 
governs binding to human TCRα as shown in J-76 (Figure 
2C/2D). This should enable the generation of scTCR 
p53/endogenous dcTCR CMV bispecific T-cells (Figure 
4D) which represent TCR-engineered T-cells of high 
therapeutic relevance in DLI of hematological diseases. 
A mechanistic proof-of-concept has been achieved for 
scTCR gp100/dcTCR CMV-bispecific J-76 cells (Figure 
3). We retrovirally transduced 2A-linked scTCR p53/
Cα or dcTCR p53 into oligoclonal pp65-specific T-cells 
enriched by pp65(495-503) peptide-stimulation from 
CMV+ donors [40]. Dc or scTCR p53 expression (Mu 
TCRβ) was prominent in the presence of the endogenous 
TCR pp65 (Tet pp65). Interestingly, dcTCR p53 led to a 
stronger decrease in multimer-staining of TCR pp65 than 
scTCR p53 (MFIy 203 vs 288). Downregulation of TCR 
pp65 is likely mediated by TCR chain mispairing with 
either TCRα or TCRβ p53, or both. Obviously, the scTCR-
design limited unwanted interference between both TCRs 
more efficiently. Moreover, we could demonstrate that 
scTCR p53 transduced T-cells secreted higher amounts 
of intracellular IFNγ than dcTCR p53 (MFIs 363 vs 
165) after pp65 antigen encounter on T2 cells almost as 
much as the mock (i.e. empty vector)-transduced CMV+ 
T-cells (MFI 502). In turn, scTCR p53-transduced T-cells 
produced more cytokine against the cognate antigen (MFI 
196) than dcTCR p53 (MFI 112) for the same reason of a 
limited hybrid TCR-formation. Conclusively, scTCR p53-
transduced CMV+ T-cells were clearly bispecific for the 
tumor- and the virus-antigen with a substantial increase 
in reactivity over dcTCR p53-transduced CMV+ T-cells. 
Protein design of a novel artificial disulfide 
bond Vα-Li(Vβ) formed between a Vα- and Vβ 
proximal linker-resident amino acid residue
Altogether, our results up to this point showed 
that mispairing of a single chain TCR with a full length 
TCRα-chain occurs on a molecular level, but is largely 
reduced under competitive conditions in human T-cells. 
In an effort to prevent so-called residual mispairing we 
Oncotarget21208www.impactjournals.com/oncotarget
Figure 4: Mispairing of a scTCR with human TCRα takes place to less amounts in human T-cells. A. 4-10 µg of RNA 
encoding Cα, human TCRα gp100, or different scTCR gp100-constructs without or with the mutation silCDR3α S109Q to eliminate 
antigen recognition, were electroporated into MACS-purified human CD8+ T-cells and 20 h later analyzed for dextramer gp100(280-288)-
positivity in flow cytometry to assess TCRα-mispairing. The overall frequency and MFI of multimer-stained T-cells in gated region is 
indicated outside the gate in bold, the frequency of multimer-positive T-cells is indicated inside in bold. Multimer-staining was performed 
twice. B. Bulk human T-cells were retrovirally transduced with different scTCR p53 (+/- silCDR3α D109A), Cα, or different TCRα-chains 
encoded on separate plasmids, normalized in TCR expression via drug-selection, expanded for at least a single 2-weekly CD3/CD28-beads 
stimulation and analyzed in tetramer p53(264-272)-binding to assess TCRα-mispairing. C. Bulk human T-cells were retrovirally transduced 
with wild type scTCR p53, Cα or antigen-un/related TCRα-chains encoded on separate plasmids and analyzed for scTCR p53 expression 
(vβ3) and antigen-recognition (tetramer p53) to assess TCR Cα-mispairing. Generation of CMV pp65/ TAA p53-bispecific T-cells. D. 
Pure pp65-specific oligoclonal T-cell populations were obtained from CMV-positive donors by repetitive peptide stimulation. DcTCRα/β- 
and scTCR/Cα p53-encoding genes, respectively, were coupled via F2A on a single plasmid carrying an IRES-puromycin cassette, and, 
along with a mock-control (i.e. empty vector), retrovirally introduced into CMV+ T-cells (top row), drug-selected to normalize TCR p53 
expression and expanded (middle row). A fraction of all T-cells loose TCR CMV-expression after selection with puromycin presumably due 
to drug-susceptibility. The resulting TCR pp65/p53-double positive (gated) T-cell subsets were assessed for specific cytokine production 
after coculture with peptide-pulsed T2-cells as indicated by means of intracellular IFNγ-staining (bottom row). This experiment is one out 
of 2 similar experiments. 
Oncotarget21209www.impactjournals.com/oncotarget
designed different disulfide bridges by visual inspection 
of empirical TCR structures (mouse 1TCR.pdb, human 
1BD2.pdb; RCSB [41]) in order to strengthen the 
interaction between the Vα- and Vβ-domain so as to 
eradicate any association to TCRα. Disulfide bridges 
are characterized by well-defined structural constraints 
such as clustering of the torsion angle χ
SS
 around 90° 
and its handedness, gauche and trans stereochemistry 
of χi and χj, respectively, and favourable Cα-distances 
between 4 and 6.2 Å for the interacting cysteines [33]. 
We tested 3 different approaches by introducing artificial 
disulfide bridges into scTCR gp100 a) directly between 
Vα and Vβ (Vα G121C / Vβ G49C according to IMGT 
nomenclature), b) between Vα and Cβ (Vα L46C / Cβ 
P82C), and c) between Vα and the C-terminal tail of the 
Gly/Ser-linker [17] at three different positions (Vα G49C 
Figure 5: Prevention of residual mispairing by a novel artificial disulfide bond designed between the Vα-domain and 
the 3’-tail of the linker close to Vβ in a 3-domain scTCR. A. Top to down side view of the human TCR crystal structure 1BD2.
pdb (RCSB). 3 different disulfide bonds have been designed, G121αC-G49βC connecting Vα and Vβ, L46αC-P82βC connecting Vα 
and Cβ and G49αC-G16-18
Li
C connecting Vα with the carboxyterminal tail of the Gly/Ser-rich 19-mer linker at 3 consecutive positions; 
T84αC-S79βC supports the interaction between the autonomously expressed TCR Cα-domain and the Cβ-domain of the 3-domain scTCR 
(black triangles). Additionally, the 4 intradomain disulfide bonds, the recognized peptide (yellow), the hypothesized conduit of the linker 
(green) and positions of its glycines 16, 17, 18 (yellow circles) which were mutated to cysteines were indicated. B. Antigen-binding of 
the wild type Chim scTCR gp100 versus Vα-Li(Vβ) cystine-modified Chim scTCR gp100 coexpressed with Cα was quantified in dose-
dependent tetramer binding saturation curves of retrovirally transduced J-76. The dissociation constant (Kd) was calculated from half-
maximal multimer binding obtained from non-linear regression analysis of the exponential saturation curve and approved for allosteric 
independency in a Scatchard analysis (inset) covering a broad and saturating tetramer concentration between 1 nM and 45 nM. The dashed 
curves illustrate narrow, non-overlapping 95% confidence intervals of the linear regression analyses reflecting a statistically significant 
difference of their slopes (P=0.022). For each data point 10.000 viable cells were recorded to calculate the MFI of antigen binding. C./D. 
Optimized TCR gp100 constructs including the novel Vα-Li(Vβ) cystine-modified Chim scTCR gp100 were retrovirally introduced into 
J-76 along with either mouse Cα or Hu Wt TCRα gp100, normalized in TCR expression via drug-selection and analyzed for their expression 
(MuTCRβ) and antigen binding (tetramer) as outlined in Figure 1(C/D). Cystine-optimized Hu Chim scTCR gp100 was analyzed in (C), 
optimized and functionally unresponsive Hu Chim scTCR gp100 silCDR3α in (D). Assignments were as described in Figure 1(C/D). The 
experiment in C and D was performed twice.
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/ Linker G16-18C) to compensate for lack of information 
about the folding characteristics of the 19 aa linker (Figure 
5A). The side chain of Vα G49C was located in β-strand 
C’ at the periphery of Vα and was protruding to an area 
where we also hypothesized the conduit of the C-terminal 
portion of the linker. The flexibility of the Gly/Ser-rich 
linker backbone was thought to appropriately allow for 
disulfide bond formation. 
Of all disulfide-bridges tested, only the Vα-linker 
engineered scTCR gp100, irrespective of the chosen 
Cys position in the Ser/Gly-linker, yielded a slightly 
better expression rate in J-76 (Figure 5C, MFI 533.3 vs 
Figure 1C, MFI 481.9) and in human T-cells (Figure 6A; 
MFI 1928 vs Figure 4A, MFI 1669) than the unmodified 
scTCR. This most likely resulted from the minimal 
effect imposed on the native TCR structure since only a 
single amino acid in Vα was modified while the second 
modification affected the artificial linker. Importantly, 
bridging Vα with the C-terminal proportion of the linker 
which is in close proximity to Vβ, resembles a direct 
linkage of Vα with Vβ, rendering them tightly associated 
and hence, was herein referred to as Vα-Li(Vβ). In an 
attempt to optimize the design of a mouse TCR, we chose 
for scTCR p53 an alternative position at Vα Q51C for 
cystine formation to G16C of the linker. This deals with 
the fact that Vα G49 in beta strand C’ faces Vβ G119 of 
beta strand G very closely while Vα Q51 permits more 
space to accommodate a cystine bridge.
We quantified the structural avidities of Chim 
scTCR gp100 + Cα versus Chim scTCR gp100 Vα-
Li(Vβ) + Cα to the cognate antigen by means of a tetramer 
saturation binding assay in flow cytometry analysis. We 
took advantage of J-76 cells to ensure the absence of 
potentially interfering endogenous TCRs (Figure 5B). 
Independence of cooperative effects in the dose-dependent 
multivalent multimer binding process was verified in 
Scatchard-analysis (Figure 5B, inset) giving a reasonable 
linearity for a broad range of tetramer concentrations. The 
introduction of the novel disulfide bond into Chim scTCR 
gp100 + Cα led to a slight increase of its avidity as read 
out by the lower equilibrium dissociation constant (Kd) in 
non-linear regression analysis (9.1±0.7 nM) versus Chim 
scTCR gp100 + Cα engineered J-76 (9.6±1.2 nM) which 
corresponded to a statistically significant difference of 
their slopes in Scatchard-analysis (Kd = -1/slope, P=0.022). 
There is also a trend for scTCR p53 Vα-Li(Vβ) + Cα (Kd 
= 9.0±3.7 nM) versus scTCR p53 + Cα (Kd = 9.4±4.2 nM) 
albeit less stringent (P=0.214, data not shown).
Initial mispairing analyses of the disulfide optimized 
scTCR gp100 Vα-Li(Vβ) were performed in J-76 by 
retroviral transduction (Figure 5C/5D) in analogy to 
experiments outlined in Figure 1C/1D. In compliance with 
Scatchard-analysis, expression and antigen recognition of 
scTCR + Cα was somewhat lower (Figure 1C left, MFIx 
481.9, 239.1) than for the optimized single chain TCR 
(Figure 5C left, MFIx 533.3, 249.7). However, this was 
not true for the S109Q-silenced scTCR probably due to 2 
amino acid replacements impacting on its native structure 
(Figure 5D left, MFI 358.4 versus Figure 1D left, 410.6). 
Mispairing with Hu TCRα decreased by more than a factor 
of 6 (533.3/59.8; 358.4/54.2) for the optimized scTCR 
gp100 irrespective of being silenced in CDR3α or not 
(Figure 5C/5D middle) in contrast to less than a factor of 
4 (481.9/125.9; 410.6/125.1) for the non-modified scTCR 
(Figure 1C/1D middle). Reduction in TCRβ-staining also 
correlated to a decrease in CD3-export to the cell surface. 
Importantly, this also translates to the complete extinction 
of residual tetramer binding (Figure 1D right, MFI 39.7) 
for the optimized scTCR (Figure 5D right, MFI 18.1) and 
IFNγ-secretion in J-76 (data not shown).
Prevention of residual mispairing in human 
T-cells by incorporating the Vα-Li(Vβ) disulfide 
bond into a human scTCR gp100
Next, we analyzed the more relevant situation in 
TCR gp100 RNA-electroporated CD8+ human T-cells 
(Figure 6A) by dextramer staining correspondingly to 
Figure 4A. The formation of the cystine bridge led to a 
somewhat better expression of the optimized scTCR gp100 
(Figure 6A, MFI 1928) in relation to the dcTCR gp100 
(MFI 1502). However, scTCR Vα-Li(Vβ) elicited by 
analogy with the unmodified scTCR a modest multimer-
staining most-likely resulting from TCR Cα-mispairing 
(46.6%, MFI 979). Mock control scTCR silCDR3α 
S109Q + Cα proved a background staining of about 3% 
(MFI 123) such as the mock control in Figure 4A (3.2%). 
Most importantly, optimized scTCR silCDR3α S109Q + 
TCRα gp100 did not exhibit any multimer positivity above 
background (2.9%, MFI 124) originating from TCRα-
mispairing. Thus, introduction of the scTCR fragment-
stabilizing disulfide bond abolished residual mispairing 
in terms of multimer-staining ranging around 4.2% (7.3% 
- ~3.1%) (Figures 4A vs 6A). 
We also tested this design in a peptide-titrated 
luciferase-based cytotoxicity-assay (Figure 6B). The 
scTCRs with or without the stabilizing cystine bridge Vα-
Li(Vβ) proved to be as cytotoxic as the wild type dc TCR 
gp100 (left, EC
50
 1.8 nM versus 1.7 nM). Again, residual 
mispairing of functionally unresponsive Hu Chim scTCR 
gp100 silCDR3α with wild type TCRα gp100 could be 
observed for moderate to high peptide pulses (middle, 
10-1000 nM; EC
50
 19.7 nM). Incorporation of the cystine 
bridge prevented almost entirely the formation of hybrid 
scTCR gp100/TCRα gp100 (right). This was largely 
confirmed by functional data from a peptide-titrated 
IFNγ-secretion assay (Suppl. Figure 4) and a proliferation 
assay based on peptide loading (Figure 6C I/III). Notably, 
the disulfide bond stabilized scTCR was able to equally 
recognize an A2+/gp100+ human melanoma cell line (data 
not shown) as experimentally demonstrated in more detail 
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Figure 6: Prevention of residual mispairing in human T-cells by incorporating the Vα-Li(Vβ) disulfide bond into a 
human scTCR gp100. A. 4-10 µg of RNA encoding Cα, or TCRα gp100, or different scTCR gp100-constructs including the novel 
Vα-Li(Vβ) cystine-stabilized scTCR gp100 with or without the mutation silCDR3α S109Q were RNA-electroporated into MACS-purified 
human CD8+ T-cells and 20 h later analyzed for dextramer gp100(280-288)-positivity in analogy to Figure 4A. Multimer-staining was 
performed twice. B. The most relevant scTCR gp100 constructs as used in Suppl. Figures 4A and 6A were introduced into human CD8+ 
T-cells via RNA electroporation and assessed in a luciferase-based cytotoxicity assay against autologous iDCs loaded with the peptide 
gp100(280-288) dose-dependently for an E:T-ratio of 20:1. EC
50
-values indicate peptide concentration of half-maximal lysis. Samples were 
measured in triplicates. C. The same TCR gp100 constructs as described in Suppl. Figure 4A and 6A were electroporated into quiescent 
MACS-purified CD8+ T-cells and assessed for their ability to proliferate upon gp100(280-288) antigen encounter either presented by 10-6M 
peptide-pulsed autologous iDCs (I/III) or gp100 RNA-electroporated iDCs followed by endogenously processed and HLA-A2-restricted 
antigen presentation (II/IV). Beside controls, I/II denote responder T-cells electroporated with derivatives of Hu Chim scTCR gp100 + 
Mu Cα, III/IV responder T-cells electroporated with the same derivatives + Hu Wt TCRα gp100 in place of Mu Cα. T-cells were labeled 
with the proliferation dye CFSE, and after 5 days of coculture with antigen-reprogrammed iDCs at an E:T of 10:1 dilution of CFSE was 
quantified. Representative data of duplicates are shown. A similar result was obtained in an independent experiment.
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for the unmodified Hu Chim scTCR gp100 elsewhere [17].
Residual mispairing is less prominent when taking 
into account endogenous antigen processing and 
could be prevented by incorporation of a novel 
cystine bridge
We also aimed at testing residual mispairing of TCR 
gp100 RNA-electroporated human quiescent CD8+ T-cells 
in a CFSE-based proliferation assay against either gp100 
peptide loaded immature dendritic cells (Figure 6C, rows 
I/III) or full length gp100 antigen electroporated iDCs 
(rows II/IV) for the same panel of TCR gp100-engineered 
cells such as used in Figures 4/6A. RNA electroporation 
of the full length gp100 antigen is supposed to represent 
a more physiologic situation than a saturating synthetic 
peptide pulse with respect to antigen quality, not quantity 
(due to the vast excess of electroporated RNA), because 
the antigenic protein is submitted to endogenous 
processing by the proteasome for e.g. HLA-A2-restricted 
peptide presentation [28] which may affect duration and 
mode of antigen presentation. Moreover, the longer period 
of time to mount a progressive stimulation of T-cells may 
account for a higher sensitivity of this assay: On average, 
proliferation upon antigen encounter gave rise to 4-5 
distinct daughter populations peaking between populations 
2-4 after 5 days of coculture. 
The modest dextramer positivity observed for Chim 
scTCR gp100 in Figure 4A could be confirmed by a low 
proportion of proliferating cells towards peptide loaded 
targets (III, 10.3 %) most-likely due to some TCR Cα-
mispairing with any endogenous TCRα. In case of antigen 
processing the frequency of proliferating T-cells (IV, 
2.9%) dropped down to almost background, which was 
defined here by scTCRgp100 silCDR3α + Cα (II, 1.8%). 
Noteworthy, proliferation of scTCR gp100 + Wt TCRα 
gp100-modified T-cells decreased from 56.3% for peptide-
pulsed targets to 5.1% for processed antigen-presenting 
iDCs which may still account for both, TCR Cα- and 
TCRα-mispairing. Hence, we hypothesize, that the amount 
of mispairing as it is read out for particularly high peptide 
loads (i.e. 10-6M) in standard operation protocols tends to 
be overestimated. 
All TCR gp100-modified T-cells being regarded as 
strong responders demonstrated almost equal and high 
proliferation rates for both, peptide loaded and antigen-
processing iDCs (row I/II, dcTCR gp100, 71.1%/64.8%, 
scTCR gp100 + Cα, 77.8%/68.4%, scTCR Vα-Li(Vβ) 
+ Cα, 71.2%/62.7%). Elevated amounts of mispairing 
with TCRα gp100 were observed only for those scTCR 
constructs which have not been optimized by a disulfide 
bond (III, scTCR + TCRα gp100, 56.3%; scTCR gp100 
sil CDR3α + TCRα gp100, 57.8 %). Introduction of the 
cystine-bridge reduced mispairing down to 21.5% for 
scTCR gp100 Vα-Li(Vβ) and 8.7% for scTCR gp100 Vα-
Li(Vβ) silCDR3α, respectively, for gp100 peptide-pulsed 
cells (III). However, this corresponded not to background 
defined here by scTCRgp100 silCDR3α + Cα (I, 1.6%). 
In case of antigen-processing (IV) hybrid TCR-formation 
in those responder cells declined to 2.9% and 1.6%, 
respectively, the latter one which, most importantly, equals 
background staining (I/II): The lower percentages for the 
CDR3α-silenced versus the functionally responsive ones 
(i.e. IV, 3.5 vs 5.1%) and also for the panel of cystine-
un/modified (i.e. III, 8.7 vs 21.5%; IV, 1.6% vs 2.9%) 
scTCR constructs could be assigned to TCRα-mispairing 
alone versus TCRα- + TCR Cα-mispairing in line with 
conclusions drawn from dextramer stainings (Figures 
4A/6A). In summary, true residual TCRα mispairing 
which took place in the range of 1.7% (i.e. IV-II, 3.5%-
1.8%) was eliminated by introducing such kind of a 
stabilizing Vα-Li(Vβ) disulfide bond (i.e. IV, 1.6%) in an 
experimental setting of endogenous antigen presentation. 
Residual mispairing could not be avoided by 
2A-linkage of mouse scTCR p53/Cα in human 
T-cells but by incorporating the novel disulfide 
bond
Subsequently, we also assessed whether a related 
Vα-Li(Vβ) disulfide bond in scTCR p53 achieved a 
similar favourable effect on residual mispairing in a 
retroviral vector system encoding scTCR p53-F2A-
Mu Cα on a single plasmid (Figure 7). Meanwhile, 
2A-constructs were routinely used in the clinic to 
introduce cancer-specific dcTCRs into human T-cells [42]. 
The genetic linkage of Mu Cα via 2A to the scTCR p53 
was thought to kinetically favor interaction of the latter 
with Cα in cis over any endogenous TCRα provided in 
trans in a cell during protein biosynthesis and thus, to 
prevent mispairing. TCR p53 is a CD8-independent high 
affinity TCR originating from A2-transgenic mice and 
hence, stains CD8+ and CD4+ T-cells [31]. However, in 
flow cytometry analysis (Figure 7A) we still observed 
considerable mispairing with TCRα (MFI, CD4+ 16.9; 
CD8+ 39.0) with reference to scTCR p53 + Mu Cα (MFI, 
CD4+ 35.8; CD8+ 53.1). Introduction of the cystine 
modification Vα-Li(Vβ) into scTCR p53 was able to 
largely reduce residual mispairing (MFI, CD4+ 4.5; CD8+ 
6.5). The same TCR p53 constructs have been tested in a 
peptide-titrated IFNγ-ELISA (Figure 7B). Efficient IFNγ-
secretion was observed for the transduced T-cells which 
were equipped with the wild type or disulfide-optimized 
p53(264-272)-specific scTCR-2A-Cα giving rise to IFNγ 
levels of more than 1400 pg/ml at saturating peptide 
loads (i.e. >10 nM). Remarkably, unmodified scTCR p53 
silCDR3α was prone to profound mispairing with murine 
TCRα p53 resulting in IFNγ levels of more than 1200 pg/
ml. Contrary, the cystine-optimized scTCR p53 silCDR3α 
D109A, 2A-linked to Mu Cα and co-transduced with the 
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same TCRα p53, exhibited a sizable decrease, but not 
extinction, of IFNγ-secretion down to less than 400 pg/
ml. These results corresponded to the multimer-stainings 
as shown in Figure 7A. 
Surprisingly, the amount of mispairing was even 
more pronounced for a mouse TCRα p53 competitor 
than a human TCRα gp100 one based on independent 
coexpression as demonstrated in Figure 6A/6B or Suppl. 
Figure 4. Retrospectively, this most-likely resulted from a 
stronger Mu Cα/Mu Cβ- than Hu Cα/Mu Cβ-interaction 
in those hybrid TCRα/scTCRs [5, 8]. It is tempting to 
speculate, that the elimination of residual mispairing 
would have been even more impressive when a human and 
hence, less competitive TCRα p53-chain as a ‘surrogate’ 
for any endogenous one would have become available. 
Actually, the competition with a human TCRα represents 
the physiologic situation. In summary, even in a 2A-linked 
retroviral vector construct, which should kinetically assist 
chain pairing of the nascent polypeptides, a TCRα is able 
to compete with Mu Cα for binding to a scTCR. Therefore, 
a strategy such as a disulfide bond modification may also 
be required for such a clinically relevant vector design.
The novel Vα-Li(Vβ) disulfide bond improved 
the functional and structural avidity of a fragile 
scTCR pp65
Finally, we addressed the question whether such a 
cystine-modification may not only affect chain pairing but 
may also help to stabilize fragile scTCRs characterized by 
poor antigen recognition due to dissociation or unfolding 
Figure 7: Reduction of residual mispairing in human T-cells by incorporating the novel disulfide bond into a mouse 
scTCR p53. A. Different Mu Cα 2A-linked scTCR p53 constructs, either unmodified or stabilized by Vα-Li(Vβ) (Q51C-G16C), with or 
without the silencing mutation silCDR3α D109A, were either expressed alone or along with Mu Wt TCRα p53 and assessed in p53(264-
272)-specific multimer-binding. Mu Cα 2A-linked Mu Wt scTCR p53 silCDR3α w/wo Vα-Li(Vβ) served as background controls. B. The 
same scTCR p53 constructs were also assessed in an IFNγ-secretion ELISA after coculture with peptide-pulsed T2 cells dose-dependently 
at an E(Vβ3+CD8+):T-ratio of 0.1:1. Here, Mu Wt scTCR p53 silCDR3α Vα-Li(Vβ) -2A- Mu Cα served as background control. Data are 
shown as mean of duplicates.
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of their Vα/Vβ-domains [43]. We analyzed cytotoxicity 
of an optimized Chim scTCR pp65 Vα-Li(Vβ) + Cα 
compared with an unmodified scTCR pp65 generated 
from a human dcTCR [27] in a retroviral vector system in 
human T-cells (Suppl. Figure 6A). TCRβ-expression of the 
cystine-modified scTCR pp65 was slightly better than for 
the unmodified one (data not shown). Two independently 
isolated bacterial clones encoding the optimized scTCR 
pp65 were more efficient in killing pp65(495-503) peptide-
titrated T2 target cells (EC
50
 0.09 nM) than the unmodified 
scTCR pp65 (EC
50
 0.33 nM). However, lysis efficacy of 
the optimally designed dcTCR (EC
50
 0.03 nM), modified 
by murinization of its C-domains [5] and linkage of 
TCRα and TCRβ via the self-processing peptide 2A [37], 
was not fully achieved. This might demand to consider 
the combination with other well-known optimization 
strategies [43], although actually, non-optimized Hu Wt 
TCRαβ pp65 instead of Hu Chim TCRαβ pp65 2A would 
have been the more appropriate reference if available. 
Of note, the cystine modification Vα-Li(Vβ) triggered 
multimer-positivity of 2A-linked Chim scTCR pp65 / Mu 
Cα after 2 rounds of peptide restimulation (Suppl. Figure 
6B) which underlines its pivotal role in triggering proper 
protein folding. 
dIscussIon
Adoptive transfer of TCR-engineered tumor reactive 
T-cells represents a clinically effective therapeutic strategy 
[1] that may allow overcoming the lack of high affinity 
T-cells specific for self tumor associated antigens due 
to central and peripheral tolerance mechanisms [44]. 
However, this approach may have important limitations 
arising from the mispairing with endogenous TCRs. In 
this report, we assess the extent of hybrid TCR-formation 
for a single chain TCR format and identify specific 
modifications to those TCRs that reduce mispairing to 
negligible levels.
First clinical trials prove the successful eradication 
of metastatic tumors such as melanoma in some patients 
[42]. Recent experiments and trials also uncovered that 
TCRs were able to recognize the cognate antigen in normal 
tissue (on-target/off-tumor) or even may cross-react with 
related or unrelated antigen (off-target/off-tumor), which 
eventually may end up with mild to severe autoimmune 
GvHD-like symptoms [1]. Additionally, mispairing 
of introduced TCR-chains with endogenous ones may 
misguide T-cells to unforeseen immune attacks against 
self [2]. However, in none of the finalized clinical trials 
till 2010 overt autoimmune reactions due to hybrid TCR-
formation have been proven [45]. Contrary, in an OT1-
TCR-based syngeneic mouse model GvHD-like symptoms 
[3], and in a panel of human phenotyped LCLs tested 
against TCR-engineered human T-cells neo-reactivities 
attributable to TCR-mispairing have been observed [4]. 
A cellular approach to reduce the risk of mispairing 
is the dual immunoreceptor-strategy in donor lymphocyte 
infusions (DLI) of engineered CMV/HA-2-bispecific 
T-cells after bone marrow transplantation of relapsed or 
refractory leukemia CMV+ patients [32, 46]. The vast 
amount of viral antigens multiplies the activation of HA-
2-engineered T-cells while the endogenous CMV-specific 
TCR (oligo)clonality confines the number of neoantigens 
originating from mispairing with the introduced anti-
leukemic TCR. Here, we were able to demonstrate in a 
proof-of-concept for a novel single chain format, that 
indeed a scTCR of the gp100(280-288)- or p53(264-272)-
specificity was independently expressed and operative 
in the presence of a dcTCR of the CMV pp65(495-503)-
specificity. Since p53 is overexpressed in many leukemias, 
this strategy yielded scTCR/dcTCR bispecific T-cells 
valuable for DLI in hematopoietic diseases. We also 
designed a CMV pp65-specific scTCR, which required 
stabilization by a novel disulfide bond as discussed later. 
The latter, either in a dc/sc- or in a even more mutually 
exclusive sc/sc-configuration in bispecific T-cells, may be 
used in those cases where CMV-specific T-cells could not 
be isolated from these patients. 
For this, we took advantage of the coexpression 
of a in Cβ murinized (or chimerized) 3-domain Vα-
Vβ-Cβ single chain TCR, which was hypothesized to 
avoid mispairing due to sterical hindrance, along with 
an autonomously expressed murine TCR Cα-domain to 
still allow for assembly of the native TCR/CD3-complex 
(Suppl. Figure 1D; [17]) as opposed to alternative 
strategies [13]. This process is mediated by charged 
residues in their transmembrane regions among those Cα 
recruits CD3ζ2 and CD3δε as the most relevant ones [19]. 
Experiments in retrogenic mice revealed their importance 
for ITAM-dependent scalable T-cell signaling to preserve 
peripheral T-cell homeostasis [47]. The functional 
sidedness of the TCRαβ framework offers a mechanism 
by which only high antigen densities trigger dimerization 
of TCR/CD3 complexes to yield sustained T-cell signaling 
while low antigen densities give rise to only transient 
signals [48, 49]. Dimerization is supposed to be driven by 
the unusual top β-strands of Cα which again emphasizes 
the pivotal role of this domain in T-cell signaling. Thus, 
we hypothesize that titration of TCR reacticvity may also 
serve as a safeguard for specificity to prematurely abrogate 
T-cell signaling in case of ‘uncertainties’ about the self/
non-self nature of low-level antigens in contrast to the 
plain non-self origin of e.g. high-level viral antigens. 
The limiting native CD3 complex does not 
necessarily represent a fundamental drawback of this 
approach since it is not the amount but predominantly 
the affinity of the introduced TCR that confers anti-
tumor reactivity [9, 50]. Additionally, xenoreactivity 
against mouse C-domains may be overcome by minimal 
murinization to a few amino acid residues which are not 
accessible to the immune system because they are buried 
at their interface [20, 21]. Secondly, human anti-mouse 
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antibody reactions against mouse TCR p53 in a clinical 
study were confined to TCR V-domains, and not directed 
against their C-domains [51]. 
However, Aggen et al. observed elevated amounts of 
mispairing of such a 3-domain scTCR with TCRα in non-
primary T-cell lines such as a murine T-cell hybridoma 
58α-β- lacking endogenous TCRs [16, 52]. Indeed, we 
also reported on mispairing in a human Leukemia cell 
line Jurkat-76 (J-76) devoid of interfering endogenous 
TCRs (ASGCT annual meeting 2011, Seattle, USA, 
abstract #221 in Mol Ther Volume 19, issue suppl. 1). 
This unfavourable reaction has been confirmed here for 2 
scTCRs specific for gp100(280-288) and p53(264-272) of 
2 different species origins, and additionally, in 2 different 
expression systems. 
From previous studies on the folding stability of 
antibody scFv-fragments it became evident that antigen 
recognition is compromised by either dissociation of their 
V-domains due to poor interaction at their interface or by 
unfolding of either domain due to weak intrinsic stability 
[36]. These mechanisms are believed to apply also to 
scTCR-fragments to even higher amounts originating 
from a weaker folding stability of membrane resident 
TCRs which is largely governed by the TCR-subfamily 
affiliation [43, 53]. This weak point facilitates mispairing 
of a 3-domain scTCR with an endogenous TCRα-chain. 
Most importantly, in human T-cells mispairing 
of human Chim scTCR gp100 with full length human 
TCRα declined to a large degree but was still detectable. 
We reasoned that the much more complicated, namely 
TCR chain-competitive, situation in human T-cells 
may have resulted in a different outcome compared 
to the data collected in 58α-β- or J-76: The presence of 
endogenous TCRβ (beside endogenous TCRα) was 
supposed to mitigate the amount of hybrid TCRα/scTCR-
formation. Moreover, we hypothesized that the presence 
of a (1-domain) mouse Cα successfully competes with 
the weak interspecies interaction of Cα of a (2-domain) 
human TCR for binding to murine Cβ of the (chimerized 
3-domain) human scTCR. This is in line with results 
for a mouse scTCR p53, where TCRα-mispairing was 
much more pronounced when a more competitive mouse 
TCRα as opposed to a human one has been used instead. 
Even the immediate linkage of a mouse scTCR p53 to 
mouse Cα on a single genetic construct by means of a 
self-processing peptide 2A which was believed to favor 
heterodimer formation of their nascent polypeptides [37] 
did not prevent mispairing with mouse TCRα p53. This 
contradicts to the general view that the usage of 2A-linked 
dcTCR constructs represents an efficient method to 
provide not only optimal (i.e. stoichiometric) expression 
but also exclusive chain pairing of the designated ones. 
However, the whole set of results supported the idea that 
mispairing of a mouse scTCR with full length human 
TCRα is very low. This is of importance since meanwhile 
in a number of clinical trials high-affinity TCRs derived 
from A2-transgenic mice were used [42]. Nevertheless, 
a few human TCRα-chains were still able to compete 
somewhat which is consistent with previous conclusions 
drawn from the empirical evidence of interspecies hybrid 
dcTCRs [8]. Of note, a titratable competition of TCRα-
chains carrying identical TCR Cα-domains pinpoints to 
the dependency of TCRα/scTCR-chain pairing on the 
interaction forces between their TCR subfamily-affiliated 
V-domains and also possibly between their clonotypic 
CDR3α/β loops as demonstrated recently for dcTCRs [24]. 
Conclusively, our results strongly suggest that mispairing 
of a human (chimerized) scTCR with human (endogenous) 
TCRα hardly occurs and even less for a murine scTCR.
To unravel the mechanisms by which mispairing 
was reduced in human T-cells, we set up a panel of 
coelectroporated TCR-chains in J-76 to mimic the TCR 
competitive situation in human T-cells. Initially, we 
assessed the competitive strength of TCRα vs Cα for 
binding to human scTCR gp100. Although in scTCR/
Cα interaction was confined to Cα and Cβ, it could be 
detected to substantial amounts in particular against TCRα 
competitors of human origin. Hence, strategies, that have 
successfully been applied to dcTCRs to enhance chain 
pairing, i.e. the murinization of the C-domains [5] and the 
introduction of an artificial disulfide bond [6] compensate 
the lack of V-domain interaction and foster successful 
competition of Cα. In TCRβ vs scTCR gp100 competition 
experiments both, a ‘weak’ TCRα pp65 or ‘strong’ 
TCRα gp100-chain are prone to interact with either their 
thymically coevolved or an unrelated TCRβ-chain. This 
supports the notion that selfpairing to a dcTCR, even a 
weak one [24], is the superior reaction to mispairing 
with a 3-domain scTCR and, beside the aforementioned 
competitive strength of optimized Cα, helps to explain 
why scTCR/Hu TCRα-mispairing is scarcely observed in 
T-cells. 
We also addressed the question whether Cα alone 
of any endogenous TCRα is able to reconstitute the 
predefined antigen-specificity of a 3-domain scTCR (i.e. 
TCR Cα-mispairing) or full length TCRα-chain pairing 
solely takes place and reprograms antigen-specificity of 
the resulting hybrid scTCR/TCRα (i.e. TCRα-mispairing). 
To our best knowledge the former reaction has not 
experimentally been ascertained before to take place. 
Partial or temporary unfolding or dissociation of Vα by 
analogy to scFv’s [36], and/or domain rearrangements 
in TCRα may explain its incidence. In J-76, we noticed 
some TCR Cα-mispairing for a strongly competing human 
TCRα gp100 and not for a ‘weak’ human as opposed to 
a ‘stronger’, in Cα murinized TCRα pp65. However, we 
did not observe this side reaction for a mouse scTCR p53, 
but more likely full length TCRα-mispairing with murine 
TCRα, and dissociation of human TCRα, respectively. 
Hence, we hypothesize a mechanism by which the Vα-
domain of any human (endogenous) TCRα ‘senses’ the 
presence of a human or mouse Vβ-domain in a given 
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3-domain single chain TCR which implies at least transient 
access of Vα(TCRα) to Vβ(scTCR) resulting from 
V-domain dissociation and/or partial unfolding (Suppl. 
Figure 5). For the same reason, TCR Cα-mispairing with a 
human, but not mouse scTCR was also observed in human 
T-cells. We suggest, that TCR Cα-mispairing provides a 
supportive effect in gene therapy since antigen-specificity 
is preserved in marked contrast to the counter-productive 
effect of TCRα-mispairing. 
In a CFSE-based proliferation assay we observed 
mispairing to occur to much less amounts when immature 
DCs were electroporated with the full length antigen 
gp100 while recognition by the most potent TCR gp100-
engineered T-cells was preserved. Hence, endogenous 
processing of full length antigen by the proteasome 
might reflect a more physiologic situation in terms of 
antigen quality such as duration [28] or mode of antigen 
presentation. From this we conclude that peptide-loading 
of any APC, which still constitutes the most commonly 
applied method to date, might lead to an overestimate of 
true antigen recognition, here originating from mispairing 
of any TCRα with a scTCR. 
However, even a frequency of as low as 1.7% of 
antigen-responsive proliferating T-cells may pose a risk 
to develop GvHD-like symptoms in vivo. Protein design 
exploited the introduction of scTCR fragment-stabilizing 
pairs of interacting amino acid residues centered at the 
V-domains’ interface deduced from either highly stable 
antibody scFv-fragments (Vα-P50-Vβ-L50) [43, 53] or 
TCR crystal structures (Vα-Q44-Vβ-Q44) [23]. In our 
hands, these amino acid replacements led indeed to an 
improved expression of a weakly stable tight junction 
protein-specific 3-domain scTCR but largely abolished 
antigen recognition. Hence, we decided to engineer 
novel disulfide bonds between V-domains by analogy to 
a recently described cystine bridge in TCR C-domains 
[6, 54]. We were able to slightly improve structural and 
functional avidity of especially human scTCRs but most 
importantly, to eliminate residual mispairing by modeling 
an artificial disulfide bond between Vα and the C-terminal 
tail of the artificial linker close to Vβ. This leaves the 
framework residues of the wild type scTCR as much as 
possible unchanged so as not to compromise structure 
and function. A similar approach has been utilized to 
generate a more stable soluble peptide-β2m-HLA-A2 
trimer by immobilizing the peptide into the HLA peptide 
binding groove via a so-called ‘disulfide trap’ [55]. Of 
note, a weakly stable scTCR of CMV-specificity could be 
enhanced in function almost 4-fold. This novel approach 
is ideally suited to not only prevent mispairing but also 
to stabilize fragile scTCR-fragments which is a common 
characteristic of engineered TCRs [43]. 
Proteolysis of linker-attached Vα might also 
explain the association of endogenous TCRα to scTCR 
during assembly in the endoplasmic reticulum of a T-cell. 
Actually, western blot analysis in non-reducing SDS-
PAGE detected a very faint 45 kD-band which might 
originate from a proteolysed disulfide-bonded Vβ-Cβ-
S-S-Cα-fragment (supplemental in [17]). However, i) 
the largely reduced onset of scTCR mispairing in a TCR 
competitive environment such as J-76 endowed with a 
dcTCR and ii) the ample prevention of residual mispairing 
by an artificial disulfide bond strongly supports the notion 
that Vα is still covalently attached to the single chain 
TCR-fragment. 
Here, we could demonstrate that mispairing of 
a 3-domain scTCR  with any TCRα is largely reduced 
in human T-cells in contrast to artificial cell lines such 
as 58α-β- or J-76 lacking endogenous TCRs. Residual 
mispairing could be eliminated by improving scTCR 
V-domain pairing through a novel artificial disulfide bond. 
This approach may be applicable to the generation of 
bispecific T-cells for donor lymphocyte infusions. Beyond 
that, optimized 3-domain scTCRs permits the presence 
of polyclonal endogenous TCRs so as to reconcile CD3 
complex-dependent physiologic T-cell signaling with 
the prevention of hybrid TCR formation for the sake of 
definite on-target-specificity. 
MAterIAls And Methods
Peptides, antibodies, and multimeric pA2.1 
complexes
Peptides p53(264-272), gp100(280-288), 
MDM2(81-88), and pp65(495-503) were synthesized 
by Biosyntan (Berlin) or PSL (Heidelberg, GER). The 
monoclonal antibodies (mAbs) used were against Hu CD4-
, or CD8-FITC, Hu Pan TCRαβ-, Hu Vβ13.1-, Vβ14-PE 
(Beckman-Coulter, Krefeld), Hu CD3(cl. HIT3a)-FITC, 
CD8-APC-Cy7, Mu TCRβ-, Vβ3-PE, Hu IFNγ-APC (BD 
Biosciences, Heidelberg, GER). PE- or PE-Cy7-labeled 
tetrameric p53-specific or gp100 pA2.1 complexes were 
obtained from LICR (Epalinges, Switzerland), pp65(495-
503) tetramers were from Beckman-Coulter, gp100(280-
288)-specific dextramers from Immudex (Copenhagen, 
Denmark).
Plasmids, tcr cloning
For RNA-electroporation, genes encoding gp100 
[30]-, CMV IE1(316-324)- or pp65 [24]-specific TCRα 
and TCRβ were either cloned into pGEM4Z vector [34] 
via XbaI/XhoI, or a modified pST1 vector [28] via SmaI-
SfoI/BamHI. For retroviral transfer, genes encoding a 
gp100-[30], p53 [31]-, MDM2 [56]-, CMV pp65 [27, 
40]-, or AML-specific TCR [38] were cloned into a 
modified pBullet vector [8] via NcoI/BamHI or pMP71 
[27]. Restriction enzymes were from NEB (Frankfurt, 
GER). Bacterial amplification in XL1-Blue, Top10, or 
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JM109 and purification of plasmids were done according 
to manufacturer’s instructions (Agilent technologies, 
Waldbronn; Life technologies, Darmstadt; NEB, 
Frankfurt; Qiagen, Hilden, GER). Amino acid residue 
replacements in TCR coding sequences were conducted 
following the protocol of the “Quikchange Site Directed 
mutagenesis”-kit (Agilent technologies). A chimerized 
3-domain scTCR pp65 was generated from a 2A-linked 
chimerized dcTCRαβ pp65 [27] by overlap extension 
PCR. The full length antigen gp100 was isolated via RT-
PCR from a gp100+ melanoma cell line and cloned into 
pST1. All final plasmids encoding receptors and antigen 
gp100 were thoroughly sequenced (Genterprise, Mainz 
MWG-Eurofins, Ebersberg, GER). 
PbMcs and cell lines
Bulk CD4+CD8+ T-cells were obtained from buffy 
coats of Hu A2.1+ donor PBMC. For this, mononuclear 
cells were separated by Ficoll (Biochrom) gradient 
centrifugation and cryopreserved. Pure CD8+ T-cells were 
isolated from PBMCs by magnetic CD8 Microbeads 
(Miltenyi-Biotec, Bergisch-Gladbach, GER) selection, 
pure immature dendritic cells were obtained from PBMCs 
by magnetic CD14 Microbeads selection, subsequently 
differentiated to iDCs by the addition of GM-CSF (f.c. 
1000 U/ml) and IL-4 (f.c. 1000 U/ml, Miltenyi-Biotec) 
for 4 days. Human T-cells and differentiated PBMCs 
were cultivated in RPMI supplemented with 10% heat-
inactivated human AB serum and 2mM (1x) glutamine. 
The amphotropic packaging cell lines Phoenix-Ampho 
were obtained from American Type Culture Collection 
(ATCC/LGC, Wesel, GER). They were grown in 
HEPES-buffered (25 mM) DMEM supplemented 
with 1x glutamine, 1x penicillin-streptomycin, 1x 
nonessential amino acids, and 10% (v/v) FCS (Cambrex, 
Wiesbaden, GER). T2 is a human HLA-A2+ TAP-deficient 
lymphoblastoid cell line; K562-A2 is a human chronic 
myelogenous leukemia cell line transfected with HLA-A2, 
Jurkat clone 76 is a human T-cell leukemia deficient in 
TCRα and TCRβ expression [26]. All cell lines were 
maintained in RPMI 1640, 10% heat-inactivated FCS, 
2 mM glutamine, 50 µM geneticin or 1x penicillin/
streptomycin. The generation of oligoclonal CMV 
pp65(495-503)-specific T-cells were performed according 
to [40].
In vitro transcription of tcr or gp100 rnA
IVT TCR RNA was generated by 2 different 
protocols: the generation of RNA for experiments in J-76 
was as previously described [34] for a pGEM4Z-based 
RNA transcription vector. Alternatively, the generation of 
RNA for experiments in human CD8+ T-cells and iDCs 
were basically performed as described in [28] for a pST1-
based RNA transcription vector. Integrity of RNA was 
checked by photometric analysis at 260/280 nm and a 
1.5% RNA formaldehyde/MOPS-gel.
RNA electroporation of Jurkat-76, CD8+ t-cells or 
iDCs, retroviral transduction of bulk T-cells
5 x 106 J-76 cells were washed and resuspended 
in OptiMEM (Invitrogen) at 25 × 106 cells/mL. 
Electroporation was performed with the GenePulser 
Xcell system (Bio-Rad, Munich, GER) applying a square 
wave pulse of 400V, 5 ms, to 5 × 106 cells with 5μg RNA 
derived from pGEM4Z. Alternatively, up to 20 ug RNA 
derived from pST1 were electroporated into T-cells with 
a CytoPulse-PA-4000 device (BTX Harvard Apparatus, 
Holliston, MA, USA) applying a single pulse at 495V, 10 
ms, or into iDCs at 300V, 12 ms. Retroviral transduction of 
bulk CD4+/CD8+ T-cells and expansion with CD3/CD28-
beads (Life Technologies) were performed as described 
previously [8]. T-cells transduced with 2 plasmids 
encoding either TCR-chain were normalized for TCR 
expression by puromycin and neomycin drug-selection, 
T-cells transduced with F2A-linked constructs [37] were 
selected only by puromycin. Retroviral transduction and 
peptide-specific expansion of TCR-engineered T-cells 
in the backbone of pMP71 was performed as described 
in [27]: Briefly, one round of restimulation of T-cells 
(0.5x105) was achieved by coculture with irradiated feeder 
PBMCs (2x106) and 10-4M peptide-loaded T2 (2x105) for 
10 days.
Functional assays and ec50-calculations
IFN-γ ELISPOT assays of RNA electroporated 
J-76 and human T-cells against T2 and K562-A2, 
respectively, were performed in duplicate wells for 20h 
[34, 57]. Proliferation of RNA-electroporated and CFSE-
labeled (0.8 µM of 5(6)-CFDA, Life Technologies/
Molecular Probes) quiescent CD8+ T-cells upon encounter 
with gp100(280-288)-loaded or full length gp100-
electroporated iDCs were quantified by CFSE-dilution 
after 5 days of coculture for parental and daughter 
populations in flow cytometry on a CANTO II-HTS 
device in duplicates (Becton-Dickinson). IFNγ-ELISAs 
of TCR-engineered human T-cells against T2 or K562-A2 
were conducted with the “Human IFNγ OptEIA ELISA 
Set” (BD, Heidelberg)-, or the “Human IFNγ ELISA 
Ready-SET-Go” (eBioscience, Frankfurt)-kit according 
to the manufacturer’s protocol. A luciferase based 
cytotoxicity assay was performed as described elsewhere 
in detail (Omokoko et al., J. Immunol. Res., 2016, doi: 
10.1155/2016/9540975). Briefly, immature DCs were 
electroporated with luciferase IVT RNA and after 20h 
loaded with gp100 peptide (280-288) dose-dependently. 1 
x 104 peptide loaded targets were cocultured with 2 x 105 
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TCR RNA electroporated CD8+ T-cells in a 96 well plate. 
After 3 h D-luciferin (BD Biosciences) was added to each 
well. After 4 hours intracellular luciferase activity was 
assessed using a Tecan Infinite M200 reader. Lysis efficacy 
is given as percentage to the difference of minimal lysis 
defined by target cells only and maximal lysis defined 
by complete lysis of target cells with Triton X-100. EC
50
 
as a measure of the ligand concentration yielding half-
maximal IFNγ-secretion (ELISA) or lysis was calculated 
from peptide titration experiments and dose-response 
sigmoidal regression analysis according to Y = Top/(1 + 
10ˆ((logEC
50
-X))) with GraphPad Prism v5.0 (GraphPad 
Software Inc, San Diego, CA, USA).
Flow cytometry and scatchard-analysis
TCR expression was determined in flow cytometric 
analysis on FACS Calibur- or FACS Canto-, proliferation 
on HTS plugged to Canto II (BD Biosciences)-devices. 
Forward/sideward scatter was determined to gate on viable 
cells. Intracellular IFNγ-staining was performed according 
to a standard protocol of Becton-Dickinson including 
‘GolgiStop’-solution and ‘Perm/Wash’-buffer I. Antigen-
binding was quantified in dose-dependent tetramer binding 
saturation curves of retrovirally transduced J-76 strictly 
controlled by time of incubation (20 min at RT), assay 
volume (200 µl), and cell density (1x105) for each sample. 
The dissociation constant (Kd) was calculated from half-
maximal multimer binding obtained from non-linear 
regression analysis of the exponential dose-escalating 
saturation curve according to MFI=Bmax*[Tet]/(Kd + [Tet]) 
and assessed for allosteric independency in a Scatchard 
analysis, from which the Kd could be recapitulated as the 
negative inverse of its slope (Kd = -1/slope). Analyses were 
performed with Graphpad Prism v5.0.
nomenclature and graphic display of tcr 
structures and modeling
Nomenclature of TCR primary structures for 
variable domains was essentially as described in Lefranc et 
al. [35] and implemented in the IMGT database (IMGT®, 
the international ImMunoGeneTics information system®, 
http://www.imgt.org/, [58]): Mu TCR p53 was assigned 
to TRAV9D-4 and TRBV26, Hu TCR gp100 to TRAV13-
1 and TRBV27, Hu TCRs CMV pp65 to TRAV24 and 
TRBV6-5; Mu TCR MDM2 to TRAV13D-4 and TRBV19, 
Hu TCR AML to TRAV39 and TRBV19, Hu TCR CMV 
IE1 to TRAV22 and TRBV7-8.
The crystal structure atom coordinates of a Mu 
H-2Kb-restricted TCR, 1TCR [23], and a Hu HLA-
A*0201-restricted TCR, 1BD2 [59], were downloaded 
from the Research Collaboratory for Structural 
Bioinformatics (RCSB) protein data bank [41] and 
visualized and analyzed with Swiss-PdbViewer version 
3.7 [60]; amino acids such as cysteines/cystines were 
designed by exploiting the built-in option to browse a 
knowledge-based rotamer library and by adjusting the side 
chain dihedral angles through all empirical conformers. 
Atom distances, angles, and H-bond calculations have 
been computed and manually verified so as not to violate 
protein structure constraints. For graphic illustration, solid 
three-dimensionally rendered protein models have been 
compiled in POV-Ray v.3.1 (www.povray.org/povlegal.
html).
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